Global Postmenopausal Vaginal Atrophy Drugs Market 2016-2020

  • Published: Apr 2016
  • Pages: 69
  • SKU: IRTNTR8969

The 2022-2026 version of this report is just being published. Buy it now and get up to $1000 worth of free customization!

Get me the latest version! (includes COVID-19 impact)
Safe and Secure SSL Encrypted
  • 2500.00
  • USD

This market research study presents a detailed segmentation of the global postmenopausal vaginal atrophy market by drug class (topical estrogen and systemic estrogen) and by geography (the Americas, APAC, and EMEA). The key leading vendors in the market are Pfizer, Allergen, Shionogi, Novo Nordisk, and Teva Pharmaceutical.

Outlook of the postmenopausal vaginal atrophy (PVA) market

Extensive research carried out by the analysts at Technavio has shown that the global postmenopausal vaginal atrophy (PVA) market will grow at an impressive CAGR of more than 7% over the forecast period.The presence of favorable healthcare reforms in the US is one of the key factors driving this market in the coming years. The Affordable Care Act has increased the number of insured women and has been a driving factor in the treatment-seeking behavior of people with this condition. Moreover, this law provides Americans with better health security by putting in place comprehensive health insurance reforms that not only have lower health care costs but also expands the coverage. Therefore, the introduction of beneficial healthcare plans in the US will prompt more women to with PVA to seek treatment, thereby aiding in the growth of this market over the forecast period.

In this industry research report, the analysts have estimated that the paradigm shift to non-estrogenic therapies is one of the critical trends driving this market’s growth. Non-estrogenic therapies in PVA treatment are a paradigm shift from systemic estrogen treatments such as creams, patches, and gels. Moreover, the launch of late-stage pipeline products expected to shift the attention from vaginal creams and OTC classes toward vaginal tablets and oral therapies. Therefore, the growing adoption of non-estrogenic therapies will propel the growth of this market segment during the forecast period.

Segmentation by drug class and analysis of the PVA market

  • Topical estrogen
  • Systemic estrogen

The topical estrogen segment dominated the market and accounted for almost 60% of the market share. Topical estrogen supplies include vaginal creams, vaginal tablet, and vaginal ring to drive this market segment’s growth in the coming years.

Geographical segmentation and analysis of the PVA market

  • Americas
  • APAC
  • EMEA

During 2015, the Americas dominated the market and accounted for almost 86% of the market share in terms of revenue. The US was the largest revenue contributor in the region, capturing a significant portion of the global market. The new and improved healthcare system along with better economic conditions is expected to drive this market in this region. Also, the increasing awareness about the benefits of PVA products encourages people to opt for this treatment. Moreover, in developed countries such as the US, women can freely discuss their symptoms with the physician creates not only awareness but also aids in early diagnosis, thereby spurring this market’s growth by 2020.

Competitive landscape and key vendors

The global PVA market is highly competitive due to the presence of both local and international drug manufacturers. The market is open to new players and has a lot of opportunities for growth.  The competitive environment is expected to increase in due to the product extensions, new products, and new applications of the products and services provided. 

Key vendors in this market are –

  • Pfizer
  • Allergan
  • Shionogi
  • Novo Nordisk
  • Teva Pharmaceuticals

Other prominent vendors analyzed in this market research report are Bayer, Bionovo, EndoCeutics, Foamix Pharmaceuticals, Ligand Pharmaceuticals, Pantarhei Bioscience, Pep-Tonic Medical. TherapeuticsMD, and Upsher-Smith Laboratories.

Key questions answered in the report include

  • What will the market size and the growth rate be in 2020?
  • What are the key factors driving the global PVA market?
  • What are the key market trends impacting the growth of the global PVA market?
  • What are the challenges to market growth?
  • Who are the key vendors in the global PVA market?
  • What are the market opportunities and threats faced by the vendors in the global PVA market?
  • Trending factors influencing the market shares of the Americas, APAC, and EMEA.
  • What are the key outcomes of the five forces analysis of global PVA market?

Technavio also offers customization on reports based on specific client requirement

Read More Read Less

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of  the report

  • Market overview
  • Top-vendor offerings
  • Assumptions

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights
  • Key buying criteria

PART 05: Overview: Vaginal atrophy

  • Symptoms
  • Causes
  • Pathophysiology
  • Diagnosis
  • Treatment
  • Epidemiology

PART 06: Branded drug profiles

  • Activella
  • Enjuvia
  • Estrace
  • Femring
  • Premarin
  • Osphena
  • Vagifem

PART 07: Market landscape

  • Market overview
  • Market size and forecast

PART 08: Market segmentation  by drug class

  • Topical estrogen
  • Systemic estrogen

PART 09: Geographical segmentation

  • Global PVA drugs market by geographical segmentation 2015-2020
  • PVA drugs market in Americas
  • PVA drugs market in US
  • PVA drugs market in EMEA
  • PVA drugs market in Europe
  • PVA drugs market in APAC
  • PVA drugs market in Japan

PART 10: Market drivers

  • Significant unmet medical needs
  • Favorable healthcare reforms in US
  • Increase in awareness of PVA
  • Cost-effective OTC drugs

PART 11: Impact of drivers

PART 12: Market challenges

  • Patent expiry of branded products
  • Low diagnosis rates
  • Poor patient adherence
  • Side effects of drugs

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Paradigm shift to non-estrogenic therapies
  • Increased R&D
  • Patient assistance programs
  • Strategic alliances

PART 15: Vendor landscape

  • Competitive scenario
  • Market share analysis 2015
  • Pfizer
  • Allergan
  • Shionogi
  • Novo Nordisk
  • Teva Pharmaceutical
  • Other prominent vendors

PART 16: AppendixList of abbreviations

PART 17: Explore Technavio

Research Framework

Technavio presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources. The analysts have presented the various facets of the market with a particular focus on identifying the key industry influencers. The data thus presented is comprehensive, reliable, and the result of extensive research, both primary and secondary.


Primary sources

  • Manufacturers and suppliers
  • Channel partners
  • Industry experts
  • Strategic decision makers

Secondary sources

  • Industry journals and periodicals
  • Government data
  • Financial reports of key industry players
  • Historical data
  • Press releases


Data Synthesis

  • Collation of data
  • Estimation of key figures
  • Analysis of derived insights

Data Validation

  • Triangulation with data models
  • Reference against proprietary databases
  • Corroboration with industry experts



  • Market drivers
  • Market challenges
  • Market trends
  • Five forces analysis


  • Market size and forecast
  • Market segmentation
  • Geographical insights
  • Competitive landscape
Interested in this report?
Get your FREE sample now!
Safe and Secure SSL Encrypted

Single User:

2500 USD

Technavio Get the report (PDF) sent to your email within minutes.

Subscribe & Save

Get lifetime access to our
Technavio Insights

Want to customize this report?

This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time.

We offer $1000 worth of FREE customization at the time of purchase
Enquire Before Buying
  1. Home
  2. Health Care
  3. Published Report
17,000 reports available | Plans starting from just 5,000 USD | Get FREE trial>>